Pareto: Vicore - The best biotech-bottom pick
Pareto just published a 20-page long report on Vicore. They rank it as the most interesting biotech in Scandinavia. They believe it should become a multi-billion USD company. This could happen quite fast as Vicore is starting their IIb trial in 2024, which may be used for FDA application.
I like this Vicore business case summary
https://fitinvestmentideas.com/2023/06/09/vicore-raised-500-mil-sek-with-specialist-investors-stock-up-15/
I like this Vicore business case summary
https://fitinvestmentideas.com/2023/06/09/vicore-raised-500-mil-sek-with-specialist-investors-stock-up-15/
NordicGuy
16.09.2023 kl 07:54
928
SeekingAlpha is the largest investment idea site in the world.
On Friday they published an article on Vicore Pharma. As the article is behind a paywall, below is the full version.
https://fitinvestmentideas.com/2023/09/16/seekingalpha-vicore-pharma-is-leading-the-race-in-ipf-cure/
On Friday they published an article on Vicore Pharma. As the article is behind a paywall, below is the full version.
https://fitinvestmentideas.com/2023/09/16/seekingalpha-vicore-pharma-is-leading-the-race-in-ipf-cure/
NordicGuy
14.12.2023 kl 10:30
775
From Vicore´s Linkedin:
Our CEO, Ahmed Mousa, was recently featured on the Optimum Perspectives Podcast! In a conversation with Richard Staines, he delved into Vicore Pharma AB strategy for improving treatments for Idiopathic Pulmonary Fibrosis (#IPF) patients. This included insights into our upcoming phase 2b 'ASPIRE' trial, scheduled to commence first half next year.
Listen here and learn more about our commitment to revolutionising the landscape of IPF treatment: https://lnkd.in/dZWYypZM
Our CEO, Ahmed Mousa, was recently featured on the Optimum Perspectives Podcast! In a conversation with Richard Staines, he delved into Vicore Pharma AB strategy for improving treatments for Idiopathic Pulmonary Fibrosis (#IPF) patients. This included insights into our upcoming phase 2b 'ASPIRE' trial, scheduled to commence first half next year.
Listen here and learn more about our commitment to revolutionising the landscape of IPF treatment: https://lnkd.in/dZWYypZM
NordicGuy
15.12.2023 kl 11:04
726
From Vicore´s Linkedin:
Our CEO, Ahmed Mousa, was recently featured on the Optimum Perspectives Podcast! In a conversation with Richard Staines, he delved into Vicore Pharma AB strategy for improving treatments for Idiopathic Pulmonary Fibrosis (#IPF) patients. This included insights into our upcoming phase 2b 'ASPIRE' trial, scheduled to commence first half next year.
Listen here and learn more about our commitment to revolutionising the landscape of IPF treatment: https://lnkd.in/dZWYypZM
Our CEO, Ahmed Mousa, was recently featured on the Optimum Perspectives Podcast! In a conversation with Richard Staines, he delved into Vicore Pharma AB strategy for improving treatments for Idiopathic Pulmonary Fibrosis (#IPF) patients. This included insights into our upcoming phase 2b 'ASPIRE' trial, scheduled to commence first half next year.
Listen here and learn more about our commitment to revolutionising the landscape of IPF treatment: https://lnkd.in/dZWYypZM
NordicGuy
04.01.2024 kl 17:03
601
From Vicore Linkedin
Vicore Pharma AB is thrilled to share the positive results from our #COMPANION pivotal study on Almee™, a groundbreaking 9-week digital therapy for Pulmonary Fibrosis (PF) patients. The study met its primary endpoint, showcasing a significant reduction in anxiety levels and a notable improvement in quality of life.
Developed in partnership with Alex Therapeutics, Almee™ is the first digital therapy addressing the psychological burden of PF, offering personalized and accessible support to patients.
Read the full PR: https://lnkd.in/dk-8S8q8
Vicore Pharma AB is thrilled to share the positive results from our #COMPANION pivotal study on Almee™, a groundbreaking 9-week digital therapy for Pulmonary Fibrosis (PF) patients. The study met its primary endpoint, showcasing a significant reduction in anxiety levels and a notable improvement in quality of life.
Developed in partnership with Alex Therapeutics, Almee™ is the first digital therapy addressing the psychological burden of PF, offering personalized and accessible support to patients.
Read the full PR: https://lnkd.in/dk-8S8q8
NordicGuy
27.02.2024 kl 11:13
398
The new Vicore CEO is actively introducing Vicore to US investors:
Vicore to Present at Upcoming Investor Conferences
Stockholm, February 27, 2024 – Vicore Pharma Holding AB (publ), unlocking the potential of a new class of drug candidates, angiotensin II type 2 receptor agonists (ATRAGs), today announced participation in the following investor conferences:
TD Cowen 44th Annual Health Care Conference
Location: Boston, MA.
Presenter: Ahmed Mousa, CEO
Presentation Date and Time: March 6 at 12:50 PM ET/6:50 PM CET
Webcast Registration: Link
Carnegie Nordic Healthcare Seminar
Location: Stockholm, Sweden
Presenter: Mikael Nygård, VP Operations and Corporate Strategy
Presentation Date and Time: March 6 at 9:00 AM ET/3:00 PM CET
Vicore to Present at Upcoming Investor Conferences
Stockholm, February 27, 2024 – Vicore Pharma Holding AB (publ), unlocking the potential of a new class of drug candidates, angiotensin II type 2 receptor agonists (ATRAGs), today announced participation in the following investor conferences:
TD Cowen 44th Annual Health Care Conference
Location: Boston, MA.
Presenter: Ahmed Mousa, CEO
Presentation Date and Time: March 6 at 12:50 PM ET/6:50 PM CET
Webcast Registration: Link
Carnegie Nordic Healthcare Seminar
Location: Stockholm, Sweden
Presenter: Mikael Nygård, VP Operations and Corporate Strategy
Presentation Date and Time: March 6 at 9:00 AM ET/3:00 PM CET
NordicGuy
28.02.2024 kl 09:24
354
VIcore presenting in the US
https://finance.yahoo.com/news/vicore-present-upcoming-investor-conferences-072000150.html
https://finance.yahoo.com/news/vicore-present-upcoming-investor-conferences-072000150.html
NordicGuy
15.07.2024 kl 09:32
101
IDIOPATHIC PULMONARY FIBROSIS DISEASE TREATMENT INDUSTRY IS EXPECTED TO REACH $8 BILLION BY 2030 -BOEHRINGER INGELHEIM,
https://www.knowcasino.co.nz/uncategorised/idiopathic-pulmonary-fibrosis-disease-treatment-industry-is-expected-to-reach-8-billion-by-2030-boehringer-ingelheim-2/235525/
Vicore is the billion dollar business in making! Do read the thesis
https://www.knowcasino.co.nz/uncategorised/idiopathic-pulmonary-fibrosis-disease-treatment-industry-is-expected-to-reach-8-billion-by-2030-boehringer-ingelheim-2/235525/
Vicore is the billion dollar business in making! Do read the thesis